MAZE — Maze Therapeutics, Inc.
Price · 2025-01-31 → 2026-08-21
391 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2025-01-31.
Performance
Technicals
Others in Healthcare
Measured signals that fired on MAZE
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-30 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-05 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-05 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-03-27 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-13 | Bernstein Harold President, R&D & CMO | Open-market sale 10b5-1 plan | 16.1K | 27.61 | 445.6K |
| 2026-08-13 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 plan | 16.1K | 10.42 | 168.2K |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Open-market sale 10b5-1 plan | 30.3K | 26.71 | 809.5K |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Open-market sale 10b5-1 plan | 2.4K | 26.71 | 65.2K |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Open-market sale 10b5-1 plan | 1.6K | 27.09 | 43.4K |
| 2026-08-03 | Coloma Jason V Chief Executive Officer | Open-market sale 10b5-1 plan | 154 | 27.09 | 4.2K |
| 2026-07-29 | Dandekar Atul CSBO | Open-market sale 10b5-1 plan | 7.1K | 27.31 | 193.9K |
| 2026-07-29 | Dandekar Atul CSBO | Option exercise 10b5-1 plan | 7.5K | 10.42 | 78.2K |
| 2026-07-29 | Dandekar Atul CSBO | Open-market sale 10b5-1 plan | 400 | 27.89 | 11.2K |
| 2026-07-01 | Coloma Jason V Chief Executive Officer | Open-market sale 10b5-1 plan | 30.3K | 29.95 | 907.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 136.3M | 4.6M |
| TRV GP IV, LLC | 133.5M | 4.5M |
| ARCH Venture Management, LLC | 123.0M | 4.1M |
| Deep Track Capital, LP | 103.8M | 3.5M |
| JANUS HENDERSON GROUP PLC | 85.3M | 2.9M |
| Paradigm Biocapital Advisors LP | 81.9M | 2.7M |
| BlackRock, Inc. | 76.7M | 2.6M |
| a16z Capital Management, L.L.C. | 50.8M | 1.7M |
| Venrock Adviser, LLC | 47.8M | 1.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | 42.9M | 1.4M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-17 | 2026-08-13 | on EDGAR ↗ |
| 4 | 2026-08-17 | 2026-08-13 | on EDGAR ↗ |
| 3 | 2026-08-17 | 2026-08-13 | on EDGAR ↗ |
| 3 | 2026-08-17 | 2026-08-13 | on EDGAR ↗ |
| 8-K | 2026-08-17 | 2026-08-13 | on EDGAR ↗ |
| 4 | 2026-08-14 | 2026-08-13 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-11 | 2026-06-30 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Maze Therapeutics, Inc. (MAZE) filed form 8-K · 2026-08-17 · SEC EDGAR
- Maze Therapeutics, Inc. (MAZE) filed form 4 · 2026-08-17 · SEC EDGAR
- Maze Therapeutics, Inc. (MAZE) filed form 8-K · 2026-08-17 · SEC EDGAR
- Maze Therapeutics, Inc. (MAZE) filed form 3 · 2026-08-17 · SEC EDGAR
- Maze Therapeutics, Inc. (MAZE) filed form 4 · 2026-08-17 · SEC EDGAR
- Maze Therapeutics, Inc. (MAZE) filed form 3 · 2026-08-17 · SEC EDGAR
Ask the AI about MAZE
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →